Carbidopa/levodopa: Difference between revisions
Ozybolairy (talk | contribs) →External links: new links Tag: repeated addition of external links by non-autoconfirmed user |
Reverted 1 edit by Ozybolairy; Wikipedia is not a link collection. (TW) |
||
| Line 37: | Line 37: | ||
== External links == |
== External links == |
||
* [http://www.medicines.org.uk/guides/sinemet/Parkinson's%20disease/ Sinemet medicine information for patients and carers in the UK] |
|||
* [http://www.medicines.org.uk/EMC/searchresults.aspx?term=Sinemet&searchtype=QuickSearch Sinemet UK patient information Leaflet (PIL)] |
|||
* [http://www.medsafe.govt.nz/profs/Datasheet/s/Sinemettab.htm Sinemet datasheet] |
* [http://www.medsafe.govt.nz/profs/Datasheet/s/Sinemettab.htm Sinemet datasheet] |
||
Revision as of 18:16, 13 July 2010
| Combination of | |
|---|---|
| Agonist | Levodopa |
| Enzyme inhibitor | Carbidopa |
| Clinical data | |
| ATC code | |
| Identifiers | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
Carbidopa/levodopa is the combination of carbidopa and levodopa and is used to treat Parkinson's disease[1] and Dopa-Responsive Dystonia (DRD). It is sold under several brand names, including Sinemet, Parcopa, and Atamet. The generic name under the British Approved Name system is Co-careldopa.
Levodopa is converted to dopamine via the action of a naturally occurring enzyme called DOPA decarboxylase. This occurs both in the peripheral circulation and in the central nervous system after levodopa has crossed the blood brain barrier. Activation of central dopamine receptors improves the symptoms of Parkinson's Disease, however, activation of peripheral dopamine receptors causes nausea and vomiting. For this reason levodopa is usually administered in combination with a DOPA decarboxylase inhibitor, in this case carbidopa, which does not cross the blood brain barrier but prevents peripheral conversion of levodopa to dopamine and thereby reduces the unwanted peripheral side-effects of levodopa. Use of carbidopa also increases the quantity of levodopa in the bloodstream that is available to enter the brain.
See also
References
- ^ Nyholm D (2006). "Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease". Expert review of neurotherapeutics. 6 (10): 1403–11. doi:10.1586/14737175.6.10.1403. PMID 17078781.
{{cite journal}}: Unknown parameter|month=ignored (help)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |